Dec 20, 2023
|
Ardelyx, Inc. Reports Employment Inducement Grants
|
Nov 21, 2023
|
Ardelyx, Inc. Reports Employment Inducement Grants
|
Nov 21, 2023
|
Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference
|
Nov 15, 2023
|
XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia
|
Nov 13, 2023
|
Ardelyx Announces Departure of Board Member
|
Nov 10, 2023
|
Ardelyx to Participate at the Jefferies London Healthcare Conference
|
Nov 6, 2023
|
Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States
|
Nov 3, 2023
|
Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023
|
Oct 31, 2023
|
Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance
|
Oct 30, 2023
|
Ardelyx, Inc. Reports Employment Inducement Grants
|